Not independent
Tenure on this board
12.3 yrs
Meeting calendar
OVID · Special meeting · Thursday, December 11, 2025
Ovid Therapeutics Inc
8 nominees · 3 ballot items.
Three management proposals are up for vote: (1) authorization of the increase in common stock to 315,000,000, (2) issuance of Conversion Shares and Warrant Shares upon conversion of Series B Preferred Stock and exercise of Series A and B Warrants, and (3) issuance of securities to the CEO under Nasdaq rules; the board recommends voting FOR all proposals.
Market cap
$455M
1Y TSR
+422.9%
Board grade
C+
Record date
Oct 31, 2025
Filing
DEF 14A
Meeting concluded · Dec 11, 2025
Follow how the vote landed and what changed on Ovid Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Approval of the Increase in Authorized Shares of Common Stock
ManagementBoard: FORAmendment to the Certificate of Incorporation to increase the number of authorized common stock from 125,000,000 to 315,000,000.
- 2
Approval of the Conversion of Series B Preferred Stock and Exercise of the Series A Warrants and Series B Warrants
ManagementBoard: FORIssuance of the Conversion Shares upon conversion of Series B Preferred Stock and the Warrant Shares upon exercise of Series A Warrants and Series B Warrants.
- 3
Approval of the Issuance of Securities to Executive Officer, in Accordance with Nasdaq Listing Rule 5635(C
ManagementBoard: FORIssuance of Series B Preferred Stock, Series A Warrants and Series B Warrants to the Chief Executive Officer pursuant to Nasdaq Listing Rule 5635(C).
Director elections
Nominees on the ballot8
Independent
Tenure on this board
0.5 yrs
Not independent
Tenure on this board
New nominee
Independent
Tenure on this board
10.9 yrs
Independent
Tenure on this board
9.1 yrs
Also a director at
Atea Pharmaceuticals Inc (AVIR)Halozyme Therapeutics Inc (HALO)
Independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
9.1 yrs
Independent
Tenure on this board
1.4 yrs
Also a director at
Exelixis Inc (EXEL)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 5.7% | 10,714,000 | $24M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.7% | 10,714,000 | $24M |
| 3 | Affinity Asset Advisors, LLC | 5.7% | 10,636,318 | $24M |
| 4 | EVENTIDE ASSET MANAGEMENT, LLC | 5.3% | 9,916,911 | $22M |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.3% | 6,163,781 | $14M |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 3.0% | 5,533,073 | $12M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 5,258,246 | $12M |
| 8 | ADAR1 Capital Management, LLC | 2.4% | 4,544,113 | $10M |
| 9 | Saturn V Capital Management LP | 2.2% | 4,166,666 | $9M |
| 10 | FEDERATED HERMES, INC. | 1.9% | 3,571,000 | $8M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Ovid Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Ovid Therapeutics Inc 2025 special meeting?
- Ovid Therapeutics Inc (OVID) holds its 2025 special shareholder meeting on Thursday, December 11, 2025.
- What is the record date for the Ovid Therapeutics Inc 2025 meeting?
- The record date for the Ovid Therapeutics Inc 2025 meeting is Friday, October 31, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Ovid Therapeutics Inc's 2025 meeting?
- The board is presenting 8 director nominees at the Ovid Therapeutics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Ovid Therapeutics Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Ovid Therapeutics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.